In the controlled clinical trials of Diovan - valsartan, 1,214 (36.2%) of hypertensive patients treated with valsartan were 65 years and 265 (7.9%) were 75 years. No overall difference in the efficacy or safety of valsartan was observed in this patient population, but greater sensitivity of some older individuals cannot be ruled out.

Of the 2,511 patients with heart failure randomized to valsartan in the Valsartan heart failure trial, 45% (1,141) were 65 years of age or older. There were no notable differences in efficacy or safety between older and younger patients.

Dose related orthostatic effects were seen in less than 1% of patients. An increase in the incidence of dizziness was observed in patients treated with Diovan 320 mg (8%) compared to 10 to 160 mg (2% to 4%). Diovan has been used concomitantly with hydrochlorothiazide without evidence of clinically important adverse interactions.